Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in OPTI?
OptiBiotix Health plc: THE INVESTMENT CASE

OptiBiotix: Kellogg’s move highlights the need for healthy alternative to sugar. Does one of AIM’s innovators have the answer?

The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
Frosties Box
INVESTMENT OVERVIEW: OPTI The Big Picture
As Tony would say: Frosties are Grrreat. They might be even better if they used natural, healthy sweeteners

Kellogg's said it is to cut the amount of sugar in its three top-sellers ­- Coco Pops, Rice Krispies and Rice Krispies Multi-Grain Shapes - by 20-40%. It’s also told the world last week will also stop selling Ricicles and end on-pack promotions aimed at children on Frosties.

The move comes amid pressure on food firms to cut sugar levels to combat obesity, which will be music to the ears of management of one of AIM’s most innovative companies: OptiBiotix Health plc (LON:OPTI).

It is developing natural sweet prebiotics that can be used to replace sugar in food and drinks.  These may be classified as dietary fibres, which from an industry and consumer perspective, creates the prospect of substituting high-calorie sugars with sweet, healthy fibres.

Growing interest in natural sweeteners

Chief executive Stephen O’Hara told Proactive: “With growing consumer interest in healthy lifestyles public interest and political concerns over traditional sugars and artificial sweeteners OptiBiotix is leading research in an area of growing industry interest.”

The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

With this in mind, it is developing compounds to tackle obesity, high cholesterol and diabetes.

SkinBioTherapeutics spun off 

After spinning off its SkinBio business as a separately listed entity earlier this year, the group is now focused on three development areas.

They are OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

The current year has been one of significant commercial progress, including product launches and sales agreements.

In November it inked a deal with an offshoot of Premier Foods that makes Birds Custard.

Knighton Foods will improve the formulation of Opti’s SlimBiome weight loss product so it tastes better and dissolves more easily. This will tap the product into the firm’s network of customers, which includes the major supermarket chains.

Tata too

Opti also has an alliance with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.

LPLDL is another of its innovations that is gaining market traction.

OptiBiotix struck a profit-sharing deal with Italian firm Sacco to manufacture and supply cholesterol-reducing compound and the first sales of the product were made to HLH BioPharma Vertriebs·   

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.

WATCH: OptiBiotix pair point to massive marketing opportunities 

Having created value from the SkinBio demerger recently, CEO O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

With the market for its innovations expanding by the day, this looks like a very smart idea. Or as Tony the Tiger, the smiling cartoon on the front of every Frosties box might say, ‘it’s Grrrrreat’. 

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
1504120610_biotechLatest.jpg
October 23 2017
The company is poised for a milestone-rich period over the next year or so
Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use